Shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the fifteen research firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $93.27.
Several equities analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a research report on Monday, August 17th. UBS Group set a $94.00 target price on shares of Henry Schein and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Stifel Nicolaus set a $95.00 target price on shares of Henry Schein in a report on Wednesday, August 5th. Barclays reissued an “overweight” rating and set a $100.00 target price (up from $86.00) on shares of Henry Schein in a research note on Thursday, August 6th. Finally, Piper Sandler raised their target price on shares of Henry Schein from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th.
Get Our Latest Stock Analysis on Henry Schein
Henry Schein Trading Up 1.7%
Shares of Henry Schein stock opened at $86.44 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.32 and a debt-to-equity ratio of 0.60. The firm has a market cap of $9.63 billion, a price-to-earnings ratio of 25.20, a price-to-earnings-growth ratio of 1.53 and a beta of 0.84. The business has a fifty day simple moving average of $86.60 and a 200-day simple moving average of $81.05. Henry Schein has a fifty-two week low of $62.32 and a fifty-two week high of $92.18.
Henry Schein (NASDAQ:HSIC – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.03. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%. The firm had revenue of $3.46 billion for the quarter, compared to analyst estimates of $3.37 billion. During the same period in the previous year, the company earned $1.10 earnings per share. Henry Schein’s revenue was up 6.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. On average, equities analysts forecast that Henry Schein will post 5.36 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Operose Advisors LLC acquired a new stake in shares of Henry Schein during the second quarter worth approximately $33,000. Trust Co. of Vermont acquired a new position in shares of Henry Schein in the second quarter worth $42,000. Root Financial Partners LLC acquired a new position in shares of Henry Schein in the third quarter worth $50,000. Versant Capital Management Inc raised its holdings in shares of Henry Schein by 175.4% during the second quarter. Versant Capital Management Inc now owns 617 shares of the company’s stock worth $52,000 after acquiring an additional 393 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Henry Schein by 167.4% during the first quarter. EverSource Wealth Advisors LLC now owns 936 shares of the company’s stock worth $69,000 after acquiring an additional 586 shares in the last quarter. Institutional investors own 96.62% of the company’s stock.
About Henry Schein
Henry Schein, Inc (NASDAQ: HSIC) is a global provider of healthcare products and services serving dental and medical professionals, as well as veterinary practices and laboratories. The company distributes consumable supplies, equipment, pharmaceuticals, vaccines, and other products used in clinical and practice-management settings.
In addition to product distribution, Henry Schein provides technology solutions and value-added services designed to support clinical workflows, electronic health records, practice management, procurement, equipment installation, and technical support.
See Also
- Five stocks we like better than Henry Schein
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
